Anti-FGFR2b/Topoisomerase-1 Inhibitor Antibody-drug Conjugate BG-C137

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the fibroblast growth factor receptor 2b (FGFR2b; fibroblast growth factor receptor 2 isoform IIIb; FGFR2 IIIb) conjugated to an as of yet undisclosed topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon administration of anti-FGFR2b/topoisomerase-1 inhibitor ADC BG-C137, the antibody moiety targets and binds to FGFR2b-expressing tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing FGFR2b. FGFR2b is overexpressed on certain tumor cell types.

**Synonyms:** - Anti-FGFR2b ADC BG-C137 - Anti-FGFR2b/Top-1i Inhibitor ADC BG-C137 - BG C137 - BG-C137 - BGC137 - FGFR2b-targeted ADC BG-C137